Bone disease in thyrotoxicosis

Indian Journal of Medical Research

Volumn 135, Issue 3, 2012, Pages 277-286

  Amaresh Reddy, P ^a   Harinarayan, C V ^a   Sachan, Alok ^a   Suresh, V ^a   Rajagopal, G ^a  

^a SRI VENKATESWARA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Bone formation and resorption; Thyroid; Vitamin D

Indexed keywords

ALENDRONIC ACID; ANTITHYROID AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; OSTEOCALCIN; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; RADIOACTIVE IODINE; THIAMAZOLE; THYROTROPIN; THYROXINE;

BONE DENSITY; BONE DISEASE; BONE METABOLISM; CALCIUM INTAKE; ESTROGEN THERAPY; FRACTURE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; HYPERCALCEMIA; HYPERTHYROIDISM; MINERAL METABOLISM; NODULAR GOITER; OSTEOLYSIS; OSTEOMALACIA; PARATHYROID HORMONE BLOOD LEVEL; REVIEW; SUBCLINICAL HYPERTHYROIDISM; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL;

BONE DISEASES; HUMANS; THYROTOXICOSIS;

EID: 84860370812     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. von Recklinghausen FD. Die Fibröse oder deformierende Ostitis, die Osteomalazie und die osteoplastische Carzinose in ihren gegenseitigen Beziehungen. Festchrift Rudolf Virchow (German). George Reimer, Berlin 1891. p.1.
2. Meunier PJ, S-Bianchi GG, Edouard CM. Bony manifestations of thyrotoxicosis. Orthop Clin North Am 1972; 3: 745-74.
3. Langdahl BL, Loft AG, Eriksen EF. Bone mass, bone turnover, calcium homeostasis, and body composition in surgically and radioiodine-treated former hyperthyroid patients. Thyroid 1996; 6: 169-75.
4. Krolner B, Jorgensen JV, Nielsen SP. Spinal bone mineral content in myxoedema and thyrotoxicosis. Effects of thyroid hormone(s) and antithyroid treatment. Clin Endocrinol 1983; 18: 439-46.
5. Ross DS, Neer RM, Ridgway EC, Daniels GH. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 1987; 82: 1167-70.
6. Udayakumar N, Chandrasekaran M, Rasheed M H, Suresh R V, Sivaprakash S. Evaluation of bone mineral density in thyrotoxicosis. Singapore Med J 2006; 47: 947-50.
7. Mundy GR, Shapiro JL, Bandelin JG. Direct stimulation of bone resorption by thyroid hormones. J Clin Invest 1976; 58: 529-34.
8. Rizzoli R, Poser J, Bürgi U. Nuclear thyroid hormone receptors in cultured bone cells. Metabolism 1986; 35: 71-4.
9. Sato K, Han DC, Fujii Y. Thyroid hormone stimulates alkaline phosphatase activity in cultured rat osteoblastic cells (ROS 17/2.8) through 3,5,3'-triiodo-L-thyronine nuclear receptors. Endocrinology 1987; 120: 1873-81.
10. Abu EO, Bord S, Horner A. The expression of thyroid hormone receptors in human bone. Bone 1997; 21: 137-42.
11. Britto JM, Fenton AJ, Holloway WR, Nicholson GC. Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 1994; 134: 169-76.
12. Bassett JH, O'Shea PJ, Sriskantharajah S. Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. Mol Endocrinol 2007; 21: 1095-107.
13. Abe E, Marians RC, Yu W, Wu XB. TSH is a negative regulator of skeletal remodeling. Cell 2003; 115: 151-62.
14. Lakatos P, Foldes J, Horvath C. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. J Clin Endocrinol Metab 1997; 82: 78-81.
15. Cummings SR, Nevitt MC, Browner WS. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767-73.
16. Mosekilde L, Eriksen EF, Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 1990; 19: 35-63.
17. Frizel D, Malleson A, Marks V. Plasma levels of ionised calcium and magnesium in thyroid disease. Lancet 1967; I: 1360-1.
18. Eriksen EF. Normal and pathological remodeling of human trabecular bone: Three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 1986; 7: 379-408.
19. Nielsen HE, Mosekilde L, Charles P. Bone mineral content in hyperthyroid patients after combined medical and surgical treatment. Acta Radiol Oncol Radiat Phys Biol 1979; 18: 122-8.
20. Linde J, Friis T. Osteoporosis in hyperthyroidism estimated by photon absorptiometry. Acta Endocrinol (Copenh) 1979; 91: 437-48.
21. Diamond T, Vine J, Smart R, Butler P. Thyrotoxic bone disease in women: a potentially reversible disorder. Ann Intern Med 1994; 120: 8-11.
22. Langdahl BL, Loft AG, Eriksen EF. Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy. Thyroid 1996; 6: 161-8.
23. Karga H, Papapetrou PD, Korakovouni A. Bone mineral density in hyperthyroidism. Clin Endocrinol (Oxf) 2004; 61: 466-72.
24. Hanna FW, Pettit RJ, Ammari F. Effect of replacement doses of thyroxine on bone mineral density. Clin Endocrinol 1998; 48: 229-34.
25. Toh SH, Claunch BC, Brown PH. Effect of hyperthyroidism and its treatment on bone mineral content. Arch Intern Med 1985; 145: 833-6.
26. Rosen CJ, Adler RA. Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab 1992; 75: 1531-4.
27. Grant DJ, McMurdo MET, Mole PA, Paterson CR. Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women? Clin Endocrinol 1995; 43: 339-45.
28. Lupoli G, Nuzzo V, Di Carlo C. Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. Gynecol Endocrinol 1996; 10: 343-8.
29. van der Deure WM, Uitterlinden AG, Hofman A, Rivadeneira F, Pols HA, Peeters RP, et al. Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: the Rotterdam Study. Clin Endocrinol (Oxf) 2008; 68: 175-81.
30. Wejda B, Hintze G, Katschinski, B. Hip fractures and the thyroid: a case control study. J Intern Med 1995; 237: 241-7.
31. Franklyn JA, Maisonneuve P, Sheppard MC. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 1998; 338: 712-8.
32. Vestergaard P, Rejnmark L, Weeke J, Mosekilde L. Fracture risk in patients treated for hyperthyroidism. Thyroid 2000; 10: 341-8.
33. Bauer DC, Ettinger B, Nevitt MC, Stone KL. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001; 134: 561-8.
34. Goswami R, Shah P, Ammini AC. Thyrotoxicosis with osteomalacia and proximal myopathy. J Postgrad Med 1993; 39: 89-90.
35. Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M. Thyrotoxicosis in Prepubertal Children Compared with Pubertal and Postpubertal Patients. J Clin Endocrinol Metab 2000; 85: 3678-82.
36. John F, Norman P. Use of beta-adrenergic blocking drugs in hyperthyroidism. Drugs 1984; 27: 425-46.
37. Jastrup B, Mosekilde L, Melsen F. Serum levels of vitamin D metabolites and bone remodeling in hyperthyroidism. Metabolism 1982; 31: 126-32.
38. Karsenty G, Bouchard P, Ulmann A, Schaison G. Elevated metabolic clearance rate of 1 alpha,25-dihydroxyvitamin D3 in hyperthyroidism. Acta Endocrinol (Copenh) 1985; 110: 70-4.
39. Thomas FB, Caldwell JH, Greenberger NJ. Steatorrhea in thyrotoxicosis. Relation to hypermotility and excessive dietary fat. Ann Intern Med 1973; 78: 669-75.
40. Fraser SA, Wilson GM. Plasma-calcitonin in disorders of thyroid function. Lancet 1971; I: 725-6.
41. Vasikaran SD, Talils GA, Braund WJ. Secondary hypoadrenalism presenting with hypercalcaemia. Clin Endocrinol 1994; 41: 261-4.
42. Im EJ, Lee JM, Kim JH, Chang SA, Moon SD, Ahn YB, et al. Hypokalemic Periodic Paralysis Associated with Thyrotoxicosis, Renal Tubular Acidosis and Nephrogenic Diabetes Insipidus. Endocrine J 2010; 57: 347-50.
43. Szeto CC, Chow CC, Li KY, Ko TC, Yeung VT, Cockram CS. Thyrotoxicosis and renal tubular acidosis presenting as hypokalaemic paralysis. Br J Rheumatol 1996; 35: 289-91.
44. Dash SC, Jain S, Khanna KN, Grewal KS. Thyrotoxicosis, renal tubular acidosis and renal stone. J Assoc Physicians India 1980; 28: 323-5.
45. Amato G, Mazziotti G, Sorvillo F. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone 2004; 35: 785-91.
46. Park SE, Cho MA, Kim SH. The adaptation and relationship of FGF-23 to changes in mineral metabolism in Graves' disease. Clin Endocrinol (Oxf) 2007; 66: 854-8.
47. Cooper DS, Kaplan MM, Ridgway EC. Alkaline phosphatase isoenzyme patterns in hyperthyroidism. Ann Intern Med 1979; 90: 164-8.
48. Garrel DR, Delmas PD, Malaval L, Tournaire J. Serum bone Gla protein: a marker of bone turnover in hyperthyroidism. J Clin Endocrinol Metab 1986; 62: 1052-5.
49. MacLeod JM, McHardy KC, Harvey RD. The early effects of radioiodine therapy for hyperthyroidism on biochemical indices of bone turnover. Clin Endocrinol 1993; 38: 49-53.
50. Mudde AH, Reijnders FJL, Nieuwenhuijzen Kruseman AC. Peripheral bone density in women with untreated multinodular goitre. Clin Endocrinol 1992; 37: 35-9.
51. Földes J, Tarján G, Szathmari M. Bone mineral density in patients with endogenous subclinical hyperthyroidism: Is this thyroid status a risk factor for osteoporosis? Clin Endocrinol 1993; 39: 521-7.
52. Mudde AH, Houben JHM, Kruseman ACN. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol 1994; 41: 421-4.
53. Faber J, Jensen IW, Petersen L. Normalization of serum thyrotropin by means of radioiodine treatment in subclinical hyperthyroidism: Effect on bone loss in postmenopausal women. Clin Endocrinol 1998; 48: 285-90.
54. Kumeda Y, Inaba M, Tahara H. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 2000; 85: 4157-61.
55. Diamond T, Nery L, Hales I. A therapeutic dilemma: Suppressive doses of thyroxine significantly reduce bone density measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 1991; 72: 1184-8.
56. Marcocci C, Golia F, Vignali E, Pinchera A. Skeletal muscle integrity in men chronically treated with suppressive doses of L-thyroxine. J Bone Miner Res 1997; 12: 72-7.
57. Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med 1990; 113: 265-9.
58. Pioli G, Pedrazzoni M, Palummeri E. Longitudinal study of bone loss after thyroidectomy and suppressive thyroxine therapy in premenopausal women. Acta Endocrinol 1992; 126: 238-42.
59. Stock JM, Surks MI, Oppenheimer JH. Replacement dosage of L-thyroxine in hypothyroidism. A re-evaluation. N Engl J Med 1974; 290: 529-33.
60. Paul TL, Kerrigan J, Kelly AM. Long-term L-thyroxine is associated with decreased hip bone density in premenopausal women. JAMA 1988; 259: 3137-41.
61. Franklyn J, Betteridge J, Holder R. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis. Clin Endocrinol 1994; 41: 425-32.
62. Lehmke J, Bogner U, Felsenberg D. Determination of bone mineral density by qualitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women. Clin Endocrinol 1992; 36: 511-7.
63. Gonzalez DC, Mautalen CA, Correa PH. Bone mass in totally thyroidectomized patients. Role of calcitonin deficiency and exogenous thyroid treatment. Acta Endocrinol (Copenh) 1991; 124: 521-5.
64. Stepan JJ, Limanova Z. Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment. Bone Miner 1992; 17: 377-88.
65. Marcocci C, Golia F, Bruno-Bossio G. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab 1994; 78: 818-23.
66. Garton M, Reid I, Loveridge, N. Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy. Clin Endocrinol 1994; 41: 747-55.
67. Fish LH, Schwartz HL, Cavanaugh J. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 1987; 316: 764-70.
68. Bauer DC, Nevitt MC, Ettinger B, Stone K. Low thyrotropin levels are not associated with bone loss in older women: a prospective study. J Clin Endocrinol Metab 1997; 82: 2931-6.
69. Kung AW, Lorentz T, Tam SCF. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women. Clin Endocrinol 1993; 39: 535-40.
70. De Rosa G, Testa A, Giacomini D. Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for non-toxic goitre. Clin Endocrinol 1997; 47: 529-35.
71. Muller CG, Bayley TA, Harrison JE, Tsang R. Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance. Thyroid 1995; 5: 81-7.
72. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta analysis. Eur J Endocrinol 1994; 130: 350-6.
73. Uzzan B, Campos J, Cucherat M. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996; 81: 4278-89.
74. Schneider P, Berger P, Kruse K, Börner W. Effect of calcitonin deficiency on bone density and bone turnover in totally thyroidectomized patients. J Endocrinol Invest 1991; 14: 935-42.
75. Harvey RD, McHardy KC, Reid IW. Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. J Clin Endocrinol Metab 1991; 72: 1189-94.
76. Ross DS, Ardisson LJ, Nussbaum SR, Meskell MJ. Serum osteocalcin in patients taking L-thyroxine who have subclinical hyperthyroidism. J Clin Endocrinol Metab 1991; 72: 507-9.
77. Loviselli A, Mastinu R, Rizzolo E. Circulating telopeptide type I is a peripheral marker of thyroid hormone action in hyperthyroidism and during levothyroxine suppressive therapy. Thyroid 1997; 7: 561-6.
78. Mikosch P, Obermayer-Pietsch B, Jost R. Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment. Thyroid 2003; 13: 347-56.
79. Solomon BL, Wartofsky L, Burman KD. Prevalence of fractures in postmenopausal women with thyroid disease. Thyroid 1993; 3: 17-23.
80. Leese GP, Jung RT, Guthrie C. Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol 1992; 37: 500-3.
81. Sheppard MC, Holder R, Franklyn JA. Levothyroxine treatment and occurrence of fracture of the hip. Arch Intern Med 2002; 162: 338-43.
82. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
83. Guo CY, Weetman AP, Eastell R. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol 1997; 46: 301-7.
84. Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 1992; 75: 344-50.
85. Lee MS, Kim SY, Lee MC. Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism. J Clin Endocrinol Metab 1990; 70: 766-70.
86. Kung AWC, Yeung SSC. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: The effect of calcium and calcitonin. J Clin Endocrinol Metab 1996; 81: 1232-6.
87. Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly women. Effect of estrogen. JAMA 1994; 271: 1245-9.
88. Rosen HN, Moses AC, Gundberg, C. Therapy with parental pamidronate prevents thyroid hormone-induced bone turnover in humans. J Clin Endocrinol Metab 1993; 77: 664-9.
89. Rosen H, Moses A, Garber J. Randomized trial of pamidronate in patients with thyroid cancer: Bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 1998; 83: 2324-30.
90. Hendriks JT, Smeenk D. Investigation of bone and mineral metabolism in hyperthyroidism before and after treatment using calcitonin, 47Ca and balance studies. Acta Endocrinol 1979; 91: 77-88.
91. Jodar E, Munoz-Torres M, Escobar-Jimenez F. Antiresorptive therapy in hyperthyroid patients: Longitudinal changes in bone and mineral metabolism. J Clin Endocrinol Metab 1997; 82: 1989-94.
92. Leger J, Ruiz JC, Guibourdenche J. Bone mineral density and metabolism in children with congenital hypothyroidism after prolonged L-thyroxine therapy. Acta Paediatr 1997; 86: 704-10.
93. Ribot C, Tremollieres F, Pouilles JM, Louvet JP. Bone mineral density and thyroid hormone therapy. Clin Endocrinol 1990; 33: 143-53.
94. Toh SH, Brown PH. Bone mineral content in hypothyroid male patients with hormone replacement: A 3 year study. J Bone Miner Res 1990; 5: 463-7.
95. Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly men. Arch Intern Med 1995; 155: 2005-7.
96. Coindre JM, David JP, Riviere L. Bone loss in hypothyroidism with hormone replacement. A histomorphometric study. Arch Intern Med 1986; 146: 48-53.
97. Vestergaard P, Weeke J, Hoeck HC. Fractures in patients with primary idiopathic hypothyroidism. Thyroid 2000; 10: 335-40.
98. Ross DS. Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: A randomized prospective study. Am J Med 1993; 95: 385-8.
99. Meier C, Beat M, Guglielmetti M. Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial. Osteoporos Int 2004; 15: 209-16.
100. Kung AWC, Pun KK. Bone mineral density in premenopausal women receiving long-term physiological doses of levothyroxine. JAMA 1991; 265: 2688-91.
101. Kim DJ, Khang YH, Koh JM. Low normal TSH levels are associated with low bone mineral density in healthy postmenopausal women. Clin Endocrinol (Oxf) 2006; 64: 86-90.
102. World Health Organization (WHO) study group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series No. 843. Geneva, Switzerland: WHO; 1994.
103. Harinarayan CV, Gupta N, Kochupillai N. Vitamin D status in primary hyperparathyroidism in India. Clin Endocrinol (Oxf) 1995; 43: 351-8.
104. Goswami R, Gupta N, Goswami D, Marwaha RK, Tandon N, Kochupillai N. Prevalence and significance of low 25-hydroxyvitamin D concentrations in healthy subjects in Delhi. Am J Clin Nutr 2000; 72: 472-5.
105. Harinarayan CV, Ramalakshmi T, Prasad UV, Sudhakar D, Srinivasarao PVLN, Sarma KVS. High prevalence of low-dietary calcium, high-phytate consumption, and vitamin D deficiency in healthy south Indians. Am J Clin Nutr 2007; 85: 1062-5.
106. Harinarayan CV, Joshi SR. Vitamin D status in India--its implications and remedial measures. J Assoc Physicians India 2009; 57: 40-8.
107. Arya V, Bhambari R, Godbole MM, Mithal A. Vitamin D status and its relationship with bone mineral density in healthy Asian Indians. Osteoporos Int 2004; 1: 56-61.
108. Dhanwal DK, Kochupillai N, Gupta N, Cooper C, Dennison EM. Hypovitaminosis D and bone mineral metabolism and bone density in hyperthyroidism. J Clin Densitom 2010; 13: 462-6.